(Reuters) – Sensodyne toothpaste-maker Haleon said on Thursday it expected higher revenue in 2024, thanks to firm demand for its household products ranging from painkillers, nasal sprays and multivitamins.
Haleon said its organic revenue would rise between 4%-6% this year, as the consumer healthcare company reported its first full-year results since it was spun off from GSK in 2022.
Analysts on average expect organic revenue to grow by 4.5%, according to a company-compiled consensus.
Don't miss out on any breaking news or insightful opinions!
Subscribe to our free newsletter and stay updated on the go!
By submitting this form, you are consenting to receive marketing emails from: Global Banking & Finance Review. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email.
(Reporting by Eva Mathews in Bengaluru; Editing by Subhranshu Sahu)
